Now that you know about primary, secondary, and surrogate endpoints, and have an idea how they shape treatment approvals, let’s outline the specific endpoints you’ll hear about in published studies, conversations with your specialists, or educational events about myeloma. 

The endpoints that we will deep dive in the following sections of the guide are: 

• Progression-Free Survival (PFS) 
• Overall Response Rate (ORR)
• Overall Survival (OS) 
• Safety and Tolerability 
• Quality of Life (QoL) 
• Minimal Residual Disease (MRD) negativity 
• Patient-Related Outcomes (PROs) and Real-World Data (RWD)
• Other Endpoints: Time to Progression (TTP), Duration of Response (DoR), Clinical Benefit Rate (CBR)